Tislelizumab: What It Is and Whether It Is Available in India

Tislelizumab is a PD-1 immune checkpoint inhibitor. It is a humanised IgG4 monoclonal antibody given as an intravenous infusion, sold under the brand name Tevimbra. It blocks the PD-1 brake on T cells, which is intended to let the immune system recognise certain cancers. It is a hospital medicine, not a tablet.

Most people arrive at this name because it is written on a prescription, not because they were looking for a drug class. So the plain version first: tislelizumab belongs to the same family as pembrolizumab and nivolumab. All three target PD-1. They are different molecules, made by different companies, approved for different cancers, and priced very differently in India.

It was developed by BeiGene, which now operates as BeOne Medicines. Its design difference, as described by the developer, is that the antibody is engineered to minimise binding to Fc-gamma receptors on macrophages. In India it is marketed by Glenmark Pharmaceuticals under a marketing and distribution agreement with BeiGene, and its Indian launch in June 2025 was Glenmark’s first entry into immuno-oncology.

Yes. The CDSCO approved tislelizumab, and Glenmark launched it in India as Tevimbra in June 2025. Its Indian approval covers non-small-cell lung cancer and oesophageal squamous cell carcinoma only, in defined lines of treatment. That is narrower than what the drug is approved for in the United States, Europe and China.

The regulatory trail is public. A Subject Expert Committee on oncology recommended import and marketing permission for tislelizumab injection in February 2025, and the launch followed in June 2025. New-drug approvals are listed by the CDSCO, which is the authority that decides what may be imported and marketed here.

Approved somewhere else is not approved here

This is the part worth reading twice, because online pharmacy pages get it wrong routinely. Search the brand name and you will find Indian retail listings describing it as a treatment for stomach cancer, liver cancer or Hodgkin lymphoma. Those descriptions are lifted from labels in other countries.

The picture across regulators looks like this, from each authority’s own published information as at August 2026.

Published Indian retail listings for the 100 mg vial ran from roughly ₹45,000 to ₹61,000 when checked in August 2026. A standard 200 mg dose is two vials. On those listings, the drug alone works out at roughly ₹0.9 lakh to ₹1.2 lakh for one three-weekly cycle, before any hospital charges.

That number matters most for the family who has already been told what pembrolizumab costs and has quietly decided immunotherapy is out of reach. Newer PD-1 entrants have started to move Indian pricing in this class, and tislelizumab is one of the clearest examples so far. It does not make the class cheap. It does change the arithmetic enough to be worth checking rather than assuming.

Read down that column and the shape of the change is obvious. At the listings quoted, a three-weekly tislelizumab dose costs somewhere between about a quarter and two-fifths of a three-weekly pembrolizumab dose. Nivolumab moved further and for a different reason: its Indian patent lapsed in May 2026, and a domestic biosimilar launched in January 2026 at roughly a quarter of the reference price. Pembrolizumab’s patent protection is expected to begin lapsing around 2028–29.

Three cautions before that table is used to argue for a switch.

1. Price is not the deciding variable. These medicines are not interchangeable. The approved indication, the line of treatment, the histology and any biomarker result decide which one applies. A cheaper PD-1 drug that is not approved for your cancer is not an option at any price.
2. The vial price is a fraction of the bill. Day care, nursing, pre-cycle blood tests, response-assessment scans and any chemotherapy given alongside are billed separately. Response-assessment imaging is generally coordinated at partner imaging centres rather than performed in-house.
3. Listings move, and they differ from each other. Retail pharmacy MRPs, discounted online listings, hospital pharmacy rates and any manufacturer support arrangement can all differ on the same day.

The figures above are third-party published listings and announcements, quoted so the arithmetic is visible. They are indicative, as of August 2026. They are not a hospital rate for this molecule, and no rate for it is quoted on this page. Ask for a written, itemised estimate before the first cycle, and ask separately what your insurer or scheme will and will not cover — high-cost immunotherapy is frequently capped or excluded.

Tislelizumab is given as an intravenous infusion in a day-care unit. The commonest adult schedule is a flat 200 mg every three weeks, which is two 100 mg vials. The first infusion runs over about 60 minutes; later ones may be given over about 30 minutes if the first was tolerated.

The dose is a flat dose, not a dose per kilogram of body weight. That surprises people who have been through chemotherapy, where body surface area and weight drive almost everything. The product information also describes 150 mg every two weeks, 300 mg every four weeks and 400 mg every six weeks as alternative schedules; which one is used depends on the indication and on the treating team’s plan. Why some immunotherapy drugs are dosed flat and others by weight is set out in how immunotherapy doses are calculated: mg/kg vs flat dose.

There is no home version. Some checkpoint inhibitors now exist in an under-the-skin form that shortens the visit, and that difference is explained in subcutaneous injection vs IV drip versions of immunotherapy. Tislelizumab in India is an intravenous product.

1. Before the cycle — blood tests check thyroid, liver, kidney and blood-count values, and you are asked about any new symptom since the last visit. A cycle delayed because of a blood result is routine, not a setback.
2. Review — the oncologist confirms the dose and that it is safe to proceed that day.
3. The infusion — a cannula is placed and the drug runs in, over about an hour the first time.
4. Short observation — a monitoring period for infusion reactions before you go home. Most people go home the same day.
5. Between cycles — you watch for new symptoms and report them promptly. Immune-related effects can appear weeks or months after a dose, and even after treatment has finished.

Vials are cold-chain products stored between 2 and 8 °C in the original carton. They are not frozen, not shaken, and not transported casually. If a vial is being sourced from outside the treating hospital’s own pharmacy, the cold chain and the source both need checking before it is used.

The approvals rest on the RATIONALE programme of phase 3 trials, run across lung and oesophageal cancers. Each approved setting has its own trial. Benefit is described in that programme in a proportion of patients, in the specific population studied, and not everyone in those trials responded.

That last clause is not a hedge. It is how this class works. A checkpoint inhibitor aims to remove a brake on the immune system so that it can act against the tumour; in some people it does, in some it does not, and no scan or blood test available today predicts the outcome for an individual with certainty. Anyone who tells you otherwise about any drug in this class is overselling it.

What the treating team can tell you is narrower and more useful: which indication you fall under, what the response assessment schedule will be, and what will happen if the first scan shows no benefit. Ask for those three answers before the first cycle, not after the third.

Long-term data on this molecule is still accumulating, as it is across the checkpoint-inhibitor class. Late immune-related effects, effects on fertility, and second-cancer risk after immunotherapy are areas where the evidence is genuinely immature, and any page that speaks confidently about them is going beyond what is known.

The characteristic risks are immune-related adverse events — the immune system inflaming a healthy organ. The commonest involve the thyroid, skin, gut, liver and lungs. Most are manageable when caught early. Inflammation of the lungs, bowel, heart muscle or adrenal glands is a medical emergency.

Reported common effects include fatigue, muscle or joint pain, cough, reduced appetite and weight loss, along with blood-test changes such as anaemia, a fall in lymphocyte count, low sodium, low albumin, raised blood sugar and raised liver enzymes. Many of these show on a blood report before the person feels anything, which is exactly why the pre-cycle tests are done.

Immune-related events are defined as much by when they appear as by what they are. Skin rash and thyroid changes tend to show earliest. Colitis, hepatitis and pneumonitis often appear later in a course, and some events surface weeks or months after the final dose.

Symptoms that need urgent assessment, not home management: new or worsening breathlessness, or a persistent dry cough; loose motions that increase in number or contain blood; chest pain or palpitations; severe unexplained fatigue with dizziness, vomiting or collapse; yellowing of the eyes or skin. For any of these, contact your treating oncology team immediately or go to the nearest emergency department. Do not self-medicate, and do not wait for the next scheduled cycle. Tell any doctor who sees you, in any department, that you are on immunotherapy — it changes how these symptoms are investigated.

Live vaccines are generally avoided during treatment, and steroids taken for an unrelated reason should be declared, because they interact with how this class is managed. Symptom-by-symptom guidance sits on the dedicated side-effect pages rather than here. This page is an orientation to the medicine, not a triage tool.

Tislelizumab is not the only newer PD-1 medicine changing what this class costs in India. If the question behind your search is really “is there a cheaper drug that would work for my cancer?”, read Toripalimab, Sintilimab and Other Newer PD-1 Medicines next — it covers the other entrants and, more importantly, which of them are actually approved here.

For the practical mechanics of a prescription in this class, How Immunotherapy Doses Are Calculated: mg/kg vs Flat Dose explains why the number on your prescription looks the way it does, and Subcutaneous Injection vs IV Drip Versions of Immunotherapy covers the shorter-visit forms and which drugs have them.

For the wider view across checkpoint inhibitors, biosimilars and the other medicine classes, start from Immunotherapy Medicines Explained, or from the main immunotherapy section.